Newswire (Published: Tuesday, June 20, 2017, 3:30:00 AM CDT, Received: Tuesday, June 20, 2017, 3:40:36 AM CDT)
Word Count: 400
By testing cancer DNA in the bloodstream, researchers from
The test was also used to monitor a patients blood throughout treatment to quickly determine if the cancer was evolving and thus becoming resistance to treatment.
The researchers claim the test is the first developed for a precision prostate cancer therapy targeted at specific genetic mutations with tumours, and believe it could allow the PARP inhibitor olaparib (AstraZenecas Lynparza) to become a standard treatment for advanced prostate cancer.
Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib, said Professor
From these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term. We think it could be used to make clinical decisions about whether a PARP inhibitor is working within as little as four to eight weeks of starting therapy.
Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.
However, there is still much more to understand before the potentially huge benefits of widespread precision treatment for prostate cancer will reach men in clinics across the
The study is published in the journal Cancer Discovery, and was funded by the